---
schema_version: "secwatch.filing_event.v1"
accession: "0001099800-24-000084"
form_type: "8-K"
ticker: "EW"
cik: "0001099800"
company_name: "Edwards Lifesciences Corp"
filed_at: "2024-10-24T23:59:59+00:00"
generated_at: "2026-05-30T10:20:10.323273+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Edwards Q3 sales up 9% to $1.33B; TAVR +6%, TMTT +73%; adjusted EPS $0.67 beats guidance

## Summary
- Q3 sales from continuing ops $1.33B (+9% as-reported, +10% constant currency); adjusted EPS $0.67 ahead of July guidance.
- TAVR sales $1.0B (+6% reported, +7% constant currency); TMTT sales $91M (+73%) driven by PASCAL and EVOQUE launches.
- GAAP EPS $5.13 includes one-time gain from sale of Critical Care unit; adjusted gross margin 80.7% vs 79.9% last year.
- Repurchased $1.0B of stock in Q3; remaining authorization $1.4B; cash $3.5B, debt $600M.
- Reiterated FY2024 total sales growth 8-10%; Q4 guidance: sales $1.33-1.39B, EPS $0.53-0.57.

## SEC filing metadata
- accession: 0001099800-24-000084
- form_type: 8-K
- ticker: EW
- cik: 0001099800
- company_name: Edwards Lifesciences Corp
- filed_at: 2024-10-24T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1099800/000109980024000084/0001099800-24-000084-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1099800/000109980024000084/ew-20241024.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001099800-24-000084
- JSON: https://secwatch.observer/filing/0001099800-24-000084.json
- Plain text: https://secwatch.observer/filing/0001099800-24-000084.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.